A
Andrew B. Lassman
Researcher at NewYork–Presbyterian Hospital
Publications - 70
Citations - 2073
Andrew B. Lassman is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 16, co-authored 70 publications receiving 1382 citations. Previous affiliations of Andrew B. Lassman include Columbia University Medical Center & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen,Michael Weller,Eudocia Q. Lee,Brian M. Alexander,Jill S. Barnholtz-Sloan,Floris P. Barthel,Tracy T. Batchelor,Ranjit S. Bindra,Susan M. Chang,E. Antonio Chiocca,Timothy F. Cloughesy,John DeGroot,Evanthia Galanis,Mark R. Gilbert,Monika E. Hegi,Craig Horbinski,Raymond Y. Huang,Andrew B. Lassman,Emilie Le Rhun,Michael Lim,Minesh P. Mehta,Ingo K. Mellinghoff,Giuseppe Minniti,David Nathanson,Michael Platten,Matthias Preusser,Patrick Roth,Marc Sanson,David Schiff,Susan C Short,Martin J B Taphoorn,Joerg C. Tonn,Jonathan Tsang,Roel G.W. Verhaak,Andreas von Deimling,Wolfgang Wick,Gelareh Zadeh,David A. Reardon,Kenneth Aldape,Martin J. van den Bent +39 more
TL;DR: Novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Journal ArticleDOI
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Fabio M. Iwamoto,Lauren E. Abrey,K. Beal,Philip H. Gutin,Marc K. Rosenblum,Victor E. Reuter,Lisa M. DeAngelis,Andrew B. Lassman +7 more
TL;DR: Iwamoto et al. as discussed by the authors reported on patterns of relapse and survival in patients treated with bevacizumab (BEV) for recurrent glioblastoma (GBM).
Journal ArticleDOI
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Andrew B. Lassman,Andrew B. Lassman,Stephanie L. Pugh,Mark R. Gilbert,Kenneth Aldape,Sandrine Geinoz,Jan H. Beumer,Susan M. Christner,Ritsuko Komaki,Lisa M. DeAngelis,Rakesh Gaur,Emad Youssef,Henry N. Wagner,Minhee Won,Minesh P. Mehta +14 more
TL;DR: Intraparticipant dose escalation was feasible, but dasatinib was ineffective in recurrent GBM.
Journal ArticleDOI
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin J. van den Bent,Hui K Gan,Hui K Gan,Andrew B. Lassman,Priya Kumthekar,Ryan Merrell,Nicholas Butowski,Zarnie Lwin,Tom Mikkelsen,Louis B. Nabors,Kyriakos P. Papadopoulos,Marta Penas-Prado,John Simes,Helen Wheeler,Tobias Walbert,Andrew M. Scott,Andrew M. Scott,Erica Gomez,Ho-Jin Lee,Lisa Roberts-Rapp,Hao Xiong,Earle Bain,Peter Ansell,Kyle D. Holen,David Maag,David A. Reardon +25 more
TL;DR: Depatux-m monotherapy displayed frequent but mostly Grade 1/2 ocular toxicities, and a PFS6 of 28.8% was observed in this rGBM population, warranting further study.
Journal ArticleDOI
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
David A. Reardon,Andrew B. Lassman,Martin J. van den Bent,Priya Kumthekar,Ryan Merrell,Andrew M. Scott,Lisa Fichtel,Erik P. Sulman,Erica Gomez,JuDee Fischer,Ho-Jin Lee,Wijith Munasinghe,Hao Xiong,Helen Mandich,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Hui K Gan,Hui K Gan +18 more
TL;DR: ABT-414 plus chemoradiation demonstrated an acceptable safety and pharmacokinetic profile in newly diagnosed glioblastoma and Randomized studies are ongoing to determine efficacy in Newly diagnosed and recurrent gliOBlastoma.